Angela Akers
Family · Princeton, WVNPI 1497240774
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 440 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$755
- AstraZeneca$665
- Boehringer Ingelheim$447
- Abbott$380
- plus $2K from 22 others
Across 7 payments — averaging $1361.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$10K
What the payments were for
- Food & beverage$7,021100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 98 | $1,361 |
| Novo Nordisk | 76 | $1,138 |
| Lilly USA, LLC | 51 | $755 |
| AstraZeneca | 34 | $665 |
| Boehringer Ingelheim | 24 | $447 |
| Abbott | 21 | $380 |
| Merck | 21 | $291 |
| GSK | 15 | $255 |
| Bayer | 15 | $251 |
| Amgen | 13 | $223 |
| Mylan Specialty L.p. | 10 | $199 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $170 |
| Exact Sciences | 8 | $155 |
| Novartis | 6 | $123 |
| Pfizer | 7 | $119 |
| Dexcom, Inc. | 6 | $91 |
| Amarin Pharma, Inc. | 5 | $78 |
| Biogen | 5 | $73 |
| Corium, LLC | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $28 |
| Insulet Corporation | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Almatica Pharma LLC | 1 | $23 |
| Electromed, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$120
How this compares
$7,021 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $70,520 |
| FarxigaDapagliflozin Propanediol | 47 | $54,323 |
| JardianceEmpagliflozin | 34 | $47,442 |
| Invega SustennaPaliperidone Palmitate | 14 | $42,841 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $40,365 |
| JanuviaSitagliptin Phosphate | 33 | $39,686 |
| MounjaroTirzepatide | 27 | $37,497 |
| XifaxanRifaximin | 12 | $34,578 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $34,103 |
| TrulicityDulaglutide | 19 | $21,851 |
| EliquisApixaban | 34 | $21,096 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $19,629 |
| XareltoRivaroxaban | 14 | $12,573 |
| VascepaIcosapent Ethyl | 19 | $9,939 |
| EntrestoSacubitril/Valsartan | 12 | $8,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $665 | $94,68874 claims |
| Novo NordiskOzempic | $1,138 | $70,52051 claims |
| Lilly USA, LLCMounjaro, Trulicity | $755 | $59,34846 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $28 | $55,41428 claims |
| Boehringer IngelheimJardiance | $447 | $47,44234 claims |
| MerckJanuvia | $291 | $39,68633 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $170 | $34,57812 claims |
| GSKTrelegy Ellipta | $255 | $34,10338 claims |
| PfizerEliquis | $119 | $21,09634 claims |
| NovartisEntresto | $123 | $8,10312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Princeton
- Rhonda RayPrinceton$10K
- Tracy McKenziePrinceton$8K
- Jessica MarcusPrinceton$7K
- Sabrina HuffmanPrinceton$7K
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.